Information Provided By: 
Fly News Breaks for September 29, 2015
ESPR
Sep 29, 2015 | 09:40 EDT
JMP Securities cut its price target on Esperion after the company warned that the FDA could require it to undertake new studies before its ETC-1002 is approved. However, the firm is upbeat on the disclosure of a new Phase 2 trail that will evaluate ETC-1002 as an add-on program for high intensity statin treatment as positive. It continues to be upbeat on the longer term outlook for the drug and keeps an Outperform rating.
News For ESPR From the Last 2 Days
There are no results for your query ESPR
